To Avoid ‘Booster Fatigue,’ Future COVID-19 Vaccine Doses Should Target Severe Disease
Executive Summary
CDC’s ACIP members say goal for now should not be preventing infection. FDA’s Doran Fink notes that the agency will act diligently on EUA of vaccines in children under five once it receives submissions, cites the complexity of reviewing Novavax’s EUA request for its vaccine.
You may also be interested in...
Now and Later: Administration Struggles To Cement COVID Booster Strategy Amid Evolving Pandemic
US FDA was trying to focus people on a one-booster-per year, updated fall COVID vaccine campaign to address what they perceive as the public’s inoculation exhaustion, but as BA.5 seems to be sending the US into another surge the White House is pushing a summer booster campaign.
US FDA Appears To Quickly Renege On Next-Gen COVID Vaccine Guidance With Updated Booster Announcement
After issuing guidance and making public statements saying the first updated COVID-19 vaccines would require clinical trial data, agency picks new vaccine composition that will make obtaining such data highly unlikely before a planned fall booster campaign.
Seeking To Provide ‘The Best Clarity Possible,’ ACIP Votes For COVID Vaccine Booster In Children 5-11
CDC advisory committee recommends Pfizer/BioNTech vaccine booster, but one member votes ‘no,’ citing concern that only 29% of children ages 5 to 11 have received the primary two-dose series and arguing the focus should be on additional vaccinations, not additional doses.